Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Jen Yang

Showing results (131-140 of 191) with videos related to

Pageof 20
Sort By:
BMC Pharmacology & Toxicology|December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 19, 2010
Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancerChih-Jen Yang, Yu-Jung Huang, Cheng-Yuan Wang, et al.
Cancers|November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase InhibitorsMing-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Carcinogenesis|August 20, 2013
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathwayChih-Hsin Kuo, Kuei-Fang Chen, Shah-Hwa Chou, et al.
Oncotargets and Therapy|April 5, 2016
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitorChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology|May 11, 2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyChih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, et al.
Scientific Reports|May 13, 2016
Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma PatientsMing-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Cancers|December 8, 2020
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell CarcinomaHsiao-Ling Chen, Yu-Kang Tu, Hsiu-Mei Chang, et al.
Scientific Reports|April 8, 2016
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma PatientsMing-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Plos One|July 16, 2015
Erectile Dysfunction in Patients with Sleep Apnea--A Nationwide Population-Based StudyChia-Min Chen, Ming-Ju Tsai, Po-Ju Wei, et al.
Pageof 20

Showing results (131-140 of 191) with videos related to

Sort By:
Pageof 20
BMC Pharmacology & Toxicology|December 15, 2017
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutationsChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|May 19, 2010
Antiproliferative effect of Toona sinensis leaf extract on non-small-cell lung cancerChih-Jen Yang, Yu-Jung Huang, Cheng-Yuan Wang, et al.
Cancers|November 16, 2018
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase InhibitorsMing-Ju Tsai, Jen-Yu Hung, Mei-Hsuan Lee, et al.
Carcinogenesis|August 20, 2013
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathwayChih-Hsin Kuo, Kuei-Fang Chen, Shah-Hwa Chou, et al.
Oncotargets and Therapy|April 5, 2016
Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitorChih-Jen Yang, Ming-Ju Tsai, Jen-Yu Hung, et al.
BMC Pharmacology & Toxicology|May 11, 2017
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyChih-Jen Yang, Jen-Yu Hung, Ming-Ju Tsai, et al.
Scientific Reports|May 13, 2016
Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma PatientsMing-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Cancers|December 8, 2020
Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell CarcinomaHsiao-Ling Chen, Yu-Kang Tu, Hsiu-Mei Chang, et al.
Scientific Reports|April 8, 2016
Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma PatientsMing-Ju Tsai, Ping-Hsun Wu, Chau-Chyun Sheu, et al.
Plos One|July 16, 2015
Erectile Dysfunction in Patients with Sleep Apnea--A Nationwide Population-Based StudyChia-Min Chen, Ming-Ju Tsai, Po-Ju Wei, et al.
Pageof 20